We are thrilled to announce our partnership with Charles River Laboratories. With this collaboration, we aim to perform our last pre-clinical studies to test the new administration route for Inura’s ovula before advancing to Phase I of our clinical trials. We are very grateful for this partnership and look forward to working with Charles River Laboratories!
Inura Medical AG (“Inura”) is developing a new solution for women suffering from Overactive Bladder Syndrome (OAB). OAB is a highly prevalent and disabling health disorder that significantly impacts the patient’s quality of life. For instance, sleep deprivation, fatigue, memory lapses, or embarrassment are associated with OAB symptoms. Besides, around 70-90% of the patients discontinue the available treatments because of their side effects.
Inura has designed a patented ovulum specifically for women. This pharmaceutical preparation will facilitate the drug’s effective penetration to the site of action and improve its pharmacokinetics profile. Therefore, increasing its clinical benefit and minimizing any possible side effects.
In collaboration with Inura’s partners, Charles River, and our manufacturing partner, we aim to perform our last pre-clinical studies before advancing to a Phase I clinical trial.
Charles River will conduct the final pre-clinical studies and test the new route of administration. The first step is a maximum tolerated dose study to determine the appropriate dose for a longer-term study, following a repeated dose study to generate data regarding the safety of daily treatment of the drug formulation for an extended period of 28 days.
Especially relevant for Inura’s product development is the collaboration with our manufacturing experts. In this partnership, we have refined and finalized the manufacturing process on an industrial scale and developed the formulation process to ensure the product’s success in its desired application.
We finalized the manufacturing of the pre-clinical ovula this week and are preparing for the production of the first clinical batch for the upcoming clinical trial.
Thanks to these partnerships, Inura can advance with its unique development program. This research brings the urethral ovulum closer to the market and closer to those who need it. It will allow OAB patients to change how they cope with the health disorder and regain control of their lives.
About Charles River Laboratories
Charles River provides essential products and services to help pharmaceutical, biotechnology, chemical and medical device companies, government agencies, and leading academic institutions around the globe accelerate their research, and drug development efforts. Their dedicated employees are focused on providing clients with exactly what they need to improve and expedite the discovery, early-stage development, and safe manufacture of new therapies for the patients who need them.
Inura Medical AG (“Inura”) is a Swiss start-up company with a clear vision to make a difference in women’s health. Inura’s product is an innovative, first-of-a-kind “urethral ovulum” that utilizes a novel route of drug administration to treat diseases of the bladder and lower urinary tract. Inura’s technology results from decades of work in urology by Professor Grant S. Mulholland, a renowned surgeon, academic, and past President of the American Urology Association. The first indication we are addressing with the ovulum is a chronic disease, named overactive bladder (OAB). More details on https://inuramedical.ch/.